GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Gilead Sciences Inc (BUE:GILD) » Definitions » Cyclically Adjusted Price-to-FCF

Gilead Sciences (BUE:GILD) Cyclically Adjusted Price-to-FCF : 7.52 (As of Jun. 09, 2024)


View and export this data going back to 2019. Start your Free Trial

What is Gilead Sciences Cyclically Adjusted Price-to-FCF?

As of today (2024-06-09), Gilead Sciences's current share price is ARS20203.50. Gilead Sciences's Cyclically Adjusted FCF per Share for the quarter that ended in Mar. 2024 was ARS2,685.98. Gilead Sciences's Cyclically Adjusted Price-to-FCF for today is 7.52.

The historical rank and industry rank for Gilead Sciences's Cyclically Adjusted Price-to-FCF or its related term are showing as below:

BUE:GILD' s Cyclically Adjusted Price-to-FCF Range Over the Past 10 Years
Min: 6.45   Med: 11.92   Max: 66.9
Current: 6.49

During the past years, Gilead Sciences's highest Cyclically Adjusted Price-to-FCF was 66.90. The lowest was 6.45. And the median was 11.92.

BUE:GILD's Cyclically Adjusted Price-to-FCF is ranked better than
94.41% of 322 companies
in the Drug Manufacturers industry
Industry Median: 31.865 vs BUE:GILD: 6.49

The Shiller PE Ratio was first used by professor Robert Shiller. He uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings per share of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted Price-to-FCF. The Cyclically Adjusted FCF per Share is the average of the inflation adjusted free cash flow per share of a company over the past 10 years.

Gilead Sciences's adjusted free cash flow per share data for the three months ended in Mar. 2024 was ARS1,428.264. Add all the adjusted free cash flow per share for the past 10 years together and divide 10 will get our Cyclically Adjusted FCF per Share, which is ARS2,685.98 for the trailing ten years ended in Mar. 2024.

Shiller PE for Stocks: The True Measure of Stock Valuation


Gilead Sciences Cyclically Adjusted Price-to-FCF Historical Data

The historical data trend for Gilead Sciences's Cyclically Adjusted Price-to-FCF can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Gilead Sciences Cyclically Adjusted Price-to-FCF Chart

Gilead Sciences Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Cyclically Adjusted Price-to-FCF
Get a 7-Day Free Trial Premium Member Only Premium Member Only 9.97 8.30 8.95 9.47 8.32

Gilead Sciences Quarterly Data
Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24
Cyclically Adjusted Price-to-FCF Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 8.92 8.11 7.75 8.32 7.34

Competitive Comparison of Gilead Sciences's Cyclically Adjusted Price-to-FCF

For the Drug Manufacturers - General subindustry, Gilead Sciences's Cyclically Adjusted Price-to-FCF, along with its competitors' market caps and Cyclically Adjusted Price-to-FCF data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Gilead Sciences's Cyclically Adjusted Price-to-FCF Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Gilead Sciences's Cyclically Adjusted Price-to-FCF distribution charts can be found below:

* The bar in red indicates where Gilead Sciences's Cyclically Adjusted Price-to-FCF falls into.



Gilead Sciences Cyclically Adjusted Price-to-FCF Calculation

Like the Shiller PE Ratio, the Cyclically Adjusted Price-to-FCF takes the Free Cash Flow per Share from the past 10 years, adjusts it for inflation, and then calculates the average. This average is then used for the P/FCF calculation. Because it considers this 10-year average, it's often referred to as the CAPFCF Ratio.

The Shiller PE Ratio was first used by professor Robert Shiller to measure the valuation of the overall market. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted Price-to-FCF.

Gilead Sciences's Cyclically Adjusted Price-to-FCF for today is calculated as

Cyclically Adjusted Price-to-FCF=Share Price/ Cyclically Adjusted FCF per Share
=20203.50/2685.98
=7.52

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Gilead Sciences's Cyclically Adjusted FCF per Share for the quarter that ended in Mar. 2024 is calculated as:

For example, Gilead Sciences's adjusted Free Cash Flow per Share data for the three months ended in Mar. 2024 was:

Adj_FreeCashFlowPerShare=Free Cash Flow per Share/CPI of Mar. 2024 (Change)*Current CPI (Mar. 2024)
=1428.264/131.7762*131.7762
=1,428.264

Current CPI (Mar. 2024) = 131.7762.

Gilead Sciences Quarterly Data

Free Cash Flow per Share CPI Adj_FreeCashFlowPerShare
201406 19.990 100.560 26.195
201409 20.104 100.428 26.379
201412 15.234 99.070 20.263
201503 31.350 99.621 41.469
201506 32.375 100.684 42.373
201509 23.834 100.392 31.285
201512 49.562 99.792 65.447
201603 40.885 100.470 53.624
201606 49.326 101.688 63.921
201609 46.733 101.861 60.458
201612 40.319 101.863 52.159
201703 32.784 102.862 41.999
201706 42.603 103.349 54.321
201709 34.077 104.136 43.122
201712 36.670 104.011 46.459
201803 31.414 105.290 39.317
201806 24.330 106.317 30.156
201809 57.578 106.507 71.239
201812 61.150 105.998 76.021
201903 40.827 107.251 50.163
201906 75.468 108.070 92.023
201909 107.923 108.329 131.282
201912 111.524 108.420 135.549
202003 61.825 108.902 74.811
202006 132.174 108.767 160.134
202009 123.341 109.815 148.007
202012 110.222 109.897 132.166
202103 174.521 111.754 205.788
202106 165.176 114.631 189.880
202109 241.273 115.734 274.716
202112 243.992 117.630 273.336
202203 135.534 121.301 147.238
202206 158.435 125.017 167.001
202209 298.175 125.227 313.770
202212 316.216 125.222 332.767
202303 256.141 127.348 265.048
202306 419.523 128.729 429.455
202309 454.629 129.860 461.339
202312 562.067 129.419 572.303
202403 1,428.264 131.776 1,428.264

Add all the adjusted free cash flow per share together and divide 10 will get our Cyclically Adjusted FCF per Share.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.


Gilead Sciences  (BUE:GILD) Cyclically Adjusted Price-to-FCF Explanation

Compared with the regular Price-to-Free-Cash-Flow, which works poorly for cyclical businesses, the Cyclically Adjusted Price-to-FCF smoothed out the fluctuations of free cash flow during business cycles. Therefore it is more accurate in reflecting the valuation of the company.

If a company has consistent business performance, the Cyclically Adjusted Price-to-FCF should give similar results to regular Price-to-Free-Cash-Flow.


Gilead Sciences Cyclically Adjusted Price-to-FCF Related Terms

Thank you for viewing the detailed overview of Gilead Sciences's Cyclically Adjusted Price-to-FCF provided by GuruFocus.com. Please click on the following links to see related term pages.


Gilead Sciences (BUE:GILD) Business Description

Address
333 Lakeside Drive, Foster, CA, USA, 94404
Gilead Sciences develops and markets therapies to treat life-threatening infectious diseases, with the core of its portfolio focused on HIV and hepatitis B and C. The acquisitions of Corus Pharma, Myogen, CV Therapeutics, Arresto Biosciences, and Calistoga have broadened this focus to include pulmonary and cardiovascular diseases and cancer. Gilead's acquisition of Pharmasset brought rights to hepatitis C drug Sovaldi, which is also part of combination drug Harvoni, and the Kite, Forty Seven, and Immunomedics acquisitions boost Gilead's exposure to cell therapy and noncell therapy in oncology.